XTL Biopharmaceutica Valuation
| XTLB Stock | USD 1.88 0.05 2.73% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. XTL Biopharmaceuticals maintains a prevalent Real Value of $1.67 per share. The last-minute price of the company is $1.88. Our model calculates the value of XTL Biopharmaceuticals from analyzing the company fundamentals such as Shares Owned By Insiders of 5.00 %, return on equity of -0.13, and Current Valuation of 7.2 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting XTL Biopharmaceutica's valuation include:
Price Book 3.7871 | Enterprise Value 7.2 M | Enterprise Value Ebitda 11.4232 |
Overvalued
Today
Please note that XTL Biopharmaceutica's price fluctuation is extremely dangerous at this time. Calculation of the real value of XTL Biopharmaceuticals is based on 3 months time horizon. Increasing XTL Biopharmaceutica's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since XTL Biopharmaceutica is currently traded on the exchange, buyers and sellers on that exchange determine the market value of XTL Stock. However, XTL Biopharmaceutica's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.88 | Real 1.67 | Hype 1.89 | Naive 1.72 |
The real value of XTL Stock, also known as its intrinsic value, is the underlying worth of XTL Biopharmaceuticals Company, which is reflected in its stock price. It is based on XTL Biopharmaceutica's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of XTL Biopharmaceutica's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of XTL Biopharmaceuticals Ltd helps investors to forecast how XTL stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of XTL Biopharmaceutica more accurately as focusing exclusively on XTL Biopharmaceutica's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use XTL Biopharmaceutica's intrinsic value based on its ongoing forecasts of XTL Biopharmaceutica's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against XTL Biopharmaceutica's closest peers. If more than one evaluation category is relevant for XTL Biopharmaceutica we suggest using both methods to arrive at a better estimate.
XTL Biopharmaceutica Cash |
|
XTL Valuation Trend
Comparing XTL Biopharmaceutica's enterprise value against its market capitalization is a good way to estimate the value of XTL Biopharmaceuticals Ltd uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
XTL Biopharmaceutica Total Value Analysis
XTL Biopharmaceuticals Ltd is at this time expected to have valuation of 7.2 M with market capitalization of 10.24 M, debt of 206 K, and cash on hands of 5.16 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the XTL Biopharmaceutica fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7.2 M | 10.24 M | 206 K | 5.16 M |
XTL Biopharmaceutica Asset Utilization
One of the ways to look at asset utilization of XTL is to check how much profit was generated for every dollar of assets it reports. XTL Biopharmaceuticals maintains a negative usage of resources of -0.14 (%), losing $0.001378 for each dollar of resources held by the company. Unsuccessful asset utilization attests that the company is being less efficient with each dollar of resources it maintains. Specifically, asset utilization of XTL Biopharmaceuticals Ltd shows how unproductive it operates for each dollar spent on its resources.XTL Biopharmaceutica Ownership Allocation
The market capitalization of XTL Biopharmaceuticals is $10.24 Million. XTL Biopharmaceuticals maintains 5.0 (%) of its outstanding shares held by insiders and 1.92 (%) owned by institutional investors. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.XTL Biopharmaceutica Profitability Analysis
Net Loss for the year was (1.78 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates XTL Biopharmaceutica's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in XTL Biopharmaceutica and how it compares across the competition.
About XTL Biopharmaceutica Valuation
The stock valuation mechanism determines XTL Biopharmaceutica's current worth on a weekly basis. Our valuation model uses a comparative analysis of XTL Biopharmaceutica. We calculate exposure to XTL Biopharmaceutica's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of XTL Biopharmaceutica's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -414 K | -393.3 K | |
| Pretax Profit Margin | (1.41) | (1.48) | |
| Operating Profit Margin | (1.10) | (1.15) | |
| Net Loss | (0.94) | (0.99) | |
| Gross Profit Margin | 0.62 | 0.43 |
XTL Biopharmaceutica Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 544.9 M | |
| Quarterly Earnings Growth Y O Y | -0.76 |
XTL Biopharmaceutica Current Valuation Indicators
Valuation refers to the process of determining the present value of XTL Biopharmaceuticals Ltd and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value XTL we look at many different elements of the entity such as XTL's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as XTL Biopharmaceutica, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use XTL Biopharmaceutica's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes XTL Biopharmaceutica's worth.Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |